Cardiovascular benefits The SELECT trial a landmark cardiovascular outcomes study involving over 17,000 participants showed that semaglutide reduced the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in people with obesity who did not have diabetes
Frequently Asked Questions About GLP-1 Therapy for Men Does GLP-1 therapy affect testosterone in men
This finding supports the presence of functional crosstalk between ferroptosis and inflammation
So let me cut through the hype and give you the truth about all three peptides: What they do differently, what the trials actually show, and which one makes sense for YOUR fat loss and optimization goals
People who track semaglutide results week by week often notice that energy patterns correlate closely with dietary quality
However, as science evolves, future triple agonist or even quadruple-acting peptides could demonstrate superior outcomes